T-cell clones, activated in this way, had TCRs that recognized the immunodominant encephalitogenic MBP peptide (residues 83-99) presented by HLA DR2b, thereby demonstrating the potential for causing immunopathology in HLA DR2b-positive MS patients (113). This evidence concerns the gene MBP and myeloid sarcoma.